In the first place uv á dza schv á treatment of semaglutide for the treatment of overdose á hy. It is one of the newer í ch antidiabet í k – drugs, intended ý ch for the treatment of diabetes, from the group of anal about gov glucag about nu podobn é ho peptide (GLP-1, glucagon-like peptide-1), which was found to be á that uv ä most patients arrange with í ce not very in ý razn ý , but lasted ý weight loss. Due to the epid é mii obesity, which á is in ý znamn ý m risk for az á severity of cardiovascular diseases í not only in the USA, is this assessment apparently opr á vnen é . (We have already taken over this in Os ) á nku What came out of the new antidiabetics ).
To Other antidiabetics were added to the list – inhib í tory sod í kovo-gluk about zov é ho contransport é ra 2 (SGLT-2 – sodium-glucose cotransporter 2 inhibitors). For more ý medicines in this group have been found to be favorable é ú heart development dumbbells é ho failure ur about znych skup í n patients. (This was also survived last year on Oslov ) é v čl á nku Treatment heart failure updated ).
AHA continues to remember í for two big é No í ú die, watch ú ce patients with zv ý a dream ý m krvn ý m pressure. One of them found to identify é zn í married in ý cerebrovascular sky ý ch pr í hod, cardiovascular á rnych pr í hod a ú mrt í when used í van í Sodium chloride mixtures é ho s 25% pr í dose of potassium chloride é instead of pure table salt, type ) á confirmed by í married in ý skytu cardiovascular á rnych pr í hod – vascular cerebral pr í feast if ú tnej koron á rnej pr í feast (heart attack, etc.) and hearts é his failure in the star ý ch patients with intense í externally treated ý m high ý m krvn ý m pressure with goals ý my values systolic é under 130 mmHg. (To the latter dii by sa sn á ď dalo podotkn ú that very n í blood blood ý pressure b ý va United ý u star ý ch folk í again s in ý mi nepr í subtleties and would then be useful inform á objectives of the overall ú mortality so intense í treated outside ý ch.)
Could not be mentioned ý COVID-19, treb á rs only marginally. The AHA noticed quite rarely ý in ý is multisystem é ho z á palov é ho syndr ó mu u det í (MIS-C) so z á heart rate, pľ ú c, kidney brain and more í ch org Yes in. Supports vaccinations á ciu u det í pr á in because in ý slyt myocarditis í dy (inflammation of the heart muscle) after vaccines á cii je extr é me rarely ý . And when we are already vaccinating á ciach, in á large á Thu ú dia uk á considered that vaccine á cia proti chr í pke do 72 hours í n po ak ú myocardial infarction or revascularization á cii significantly reduces the risk of further in farktu, tromb ó zy stent or ú dead during follow ú year. (O vakcin á cii proti chr í pke vs ú In connection with myocardial infarction, Donkey was mentioned earlier in á nk u Influenza vaccination protects against acute myocardial infarction ).
Today, it is technically possible to remove a blood clot from an artery that supplies blood to a part of the brain. The problem is, do it on time. (Credit: Covidien).
AHA also draws attention to Thu ú die, which é confirm ú neurol about gom už zn á me rule “time is brain”. In patients with ú ischemic cerebrovascular
Next í md about lie ý m knowledge, of í skan ý m in the past year is finding that medical ý The condition of women before pregnancy averages st á le worsens (which is not at st ú paj ú com age of parents nothing to surprise ú ce). S t ý m however st ú by nielen matersk á ú mortality which ú significantly affect ú pr á in cardiovascular disease, but it is also in ý significantly worse í general health ý condition det í chor ý ch matiek.
And finally here m á me category about giu “when less meaning á more”. S t ý we are already in cardio about gii met repeatedly. This time it is found that patients after the implant á cii koron á rny stent may no longer have í vať du á lnu antithrombotick ú treatment (anti-clotting treatment ) ý ch platelets – dual antiplatelet therapy – DAPT) cell ý year after á step, but m about I end it much en ô r . It’s not so surprising ú ce, because it resistance ú čan é annual é already í was enough “sucked out of the finger é ” and insufficiently substantiated é Thu ú diami, while the risk of á serious ý ch blood á can í vd ô the outcome of this treatment is far from negligible é . Official á This finding is now improved ý m modern features ý ch koron á stents (more about stents can be found in Article ) á nku
The story of coronary stents ). Types m additional ý m found í m is that patients with fibrils á ciou predsien í enough Come á alone é some é z “nov ý ch “direct or á anticoagulants (DOAC) without acetylsalicylic acid, which á does not contribute to improvement ú barbell, only to zv ý complicate risk reduction ú what blood á cania. (To that effect ý where that years ago threatened to determine á group of patients should already í up to three combinations á ciu antithrombot í k).
And finally, debt é years in professional ý “polypill”, a pill for patients with cardiovascular disease, who ) á would contain all the necessary é medications. Great á medzin á rodn á Thu ú dia uk á said that so á to tablet, contain ú ca simvastatin, hydrochlorothiazide, atenolol and ramipril together with a little acetylsalicylic acid reduces the risk of cardiovascular á rnej pr í feast or ú dead by up to a third. (Neuv á dza sa, prečo z á zračn á pill does not contain immediately even t ú acetylsalicylic acid pinch). Whether we actually meet her in practice, uk á that up they will be virtue.
This article á nok by far does not contain all in ý we know é Advances in Medic í not for 2021, but some that é with ú visia s cardiovascular á various diseases and up ú pay attention to the AHA. The others ú sim povudberať nabud ú ce.
By “ AHA Names Top Heart Disease and Stroke Advances for 2021 ” in Medscape Medical News , 4.1.2022.
Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here